---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-012506"
form_type: "8-K"
ticker: "AYTU"
cik: "0001385818"
company_name: "AYTU BIOPHARMA, INC"
filed_at: "2023-07-31T23:59:59+00:00"
generated_at: "2026-06-12T21:53:08.001249+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Aytu BioPharma signs exclusive deal with Medomie Pharma for ADHD drugs in Israel, Palestinian Authority

## Summary
- Exclusive collaboration, distribution and supply agreement for Adzenys XR-ODT and Cotempla XR-ODT in Israel and Palestinian Authority.
- Medomie will seek local regulatory approvals and marketing authorizations; first international commercial agreement for these ADHD products.
- Aytu CEO Josh Disbrow cites potential to improve patient compliance and reduce therapy misuse in underserved markets.
- No financial terms disclosed; export to Medomie after regulatory approvals.

## SEC filing metadata
- accession: 0001558370-23-012506
- form_type: 8-K
- ticker: AYTU
- cik: 0001385818
- company_name: AYTU BIOPHARMA, INC
- filed_at: 2023-07-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1385818/000155837023012506/0001558370-23-012506-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1385818/000155837023012506/aytu-20230731x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-012506
- JSON: https://secwatch.observer/filing/0001558370-23-012506.json
- Plain text: https://secwatch.observer/filing/0001558370-23-012506.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.